Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...

Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...